Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Subscribe

Logo for

Mol. Cell. Biol. 20 (10): 3387-3395

Copyright © 2000 by the American Society for Microbiology. All rights reserved.

Molecular and Cellular Biology, May 2000, p. 3387-3395, Vol. 20, No. 10
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain

Pipsa Saharinen,1 Kati Takaluoma,2 and Olli Silvennoinen1,2,3,*

Department of Virology, Haartman Institute, FIN-00014 University of Helsinki,1 and Institute of Medical Technology, University of Tampere,2 and Department of Clinical Microbiology, Tampere University Hospital,3 FIN-33101 Tampere, Finland

Received 11 October 1999/Returned for modification 7 December 1999/Accepted 14 February 2000

Activation of Jak tyrosine kinases through hematopoietic cytokine receptors occurs as a consequence of ligand-induced aggregation of receptor-associated Jaks and their subsequent autophosphorylation. Jak kinases consist of a C-terminal tyrosine kinase domain, a pseudokinase domain of unknown function, and Jak homology (JH) domains 3 to 7, implicated in receptor-Jak interaction. We analyzed the functional roles of the different protein domains in activation of Jak2. Deletion analysis of Jak2 showed that the pseudokinase domain but not JH domains 3 to 7 negatively regulated the catalytic activity of Jak2 as well as Jak2-mediated activation of Stat5. Phosphorylation of Stat5 by wild-type Jak2 was dependent on the SH2 domain of Stat5; however, this requirement was lost upon deletion of the pseudokinase domain of Jak2. Investigation of the mechanisms of the pseudokinase domain-mediated inhibition of Jak2 suggested that this regulation did not involve protein tyrosine phosphatases. Instead, analysis of interactions between the tyrosine kinase domain and Jak2 suggested that the pseudokinase domain interacted with the kinase domain. Furthermore, coexpression of the pseudokinase domain inhibited the activity of the single tyrosine kinase domain. Finally, deletion of the pseudokinase domain of Jak2 deregulated signal transduction through the gamma interferon receptor by significantly increasing ligand-independent activation of Stat transcription factors. These results indicate that the pseudokinase domain negatively regulates the activity of Jak2, probably through an interaction with the kinase domain, and this regulation is required to keep Jak2 inactive in the absence of ligand stimulation. Furthermore, the pseudokinase domain may have a role in regulation of Jak2-substrate interactions.

* Corresponding author. Mailing address: Department of Virology, Haartman Institute, Haartmaninkatu 3, P.O. Box 21, FIN-00014 University of Helsinki, Finland. Phone: 358-9-191 26484. Fax: 358-9-191 26491. E-mail: ltolsi{at}uta.fi.

Molecular and Cellular Biology, May 2000, p. 3387-3395, Vol. 20, No. 10
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Identification of Steroid-Sensitive Gene-1/Ccdc80 as a JAK2-Binding Protein.
E. E. O'Leary, A. M. Mazurkiewicz-Munoz, L. S. Argetsinger, T. J. Maures, H. T. Huynh, and C. Carter-Su (2013)
Mol. Endocrinol. 27, 619-634
   Abstract »    Full Text »    PDF »
Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets?.
S. N. Constantinescu and W. Vainchenker (2012)
Hematology 2012, 553-560
   Abstract »    Full Text »    PDF »
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent.
R. Andraos, Z. Qian, D. Bonenfant, J. Rubert, E. Vangrevelinghe, C. Scheufler, F. Marque, C. H. Regnier, A. De Pover, H. Ryckelynck, et al. (2012)
Cancer Discovery 2, 512-523
   Abstract »    Full Text »    PDF »
A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.
Y. Zheng, H. Qin, S. J. Frank, L. Deng, D. W. Litchfield, A. Tefferi, A. Pardanani, F.-T. Lin, J. Li, B. Sha, et al. (2011)
Blood 118, 156-166
   Abstract »    Full Text »    PDF »
Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.
S. P. Gorantla, T. N. Dechow, R. Grundler, A. L. Illert, C. M. zum Buschenfelde, M. Kremer, C. Peschel, and J. Duyster (2010)
Blood 116, 4600-4611
   Abstract »    Full Text »    PDF »
JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies.
S. S. Jatiani, S. J. Baker, L. R. Silverman, and E. P. Reddy (2010)
Genes & Cancer 1, 979-993
   Abstract »    Full Text »    PDF »
Activation of JAK2-V617F by Components of Heterodimeric Cytokine Receptors.
A. Pradhan, Q. T. Lambert, L. N. Griner, and G. W. Reuther (2010)
J. Biol. Chem. 285, 16651-16663
   Abstract »    Full Text »    PDF »
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
A. Quintas-Cardama, K. Vaddi, P. Liu, T. Manshouri, J. Li, P. A. Scherle, E. Caulder, X. Wen, Y. Li, P. Waeltz, et al. (2010)
Blood 115, 3109-3117
   Abstract »    Full Text »    PDF »
Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer.
T. Kubo, Y. Kuroda, H. Shimizu, A. Kokubu, N. Okada, F. Hosoda, Y. Arai, Y. Nakamura, H. Taniguchi, K. Yanagihara, et al. (2009)
Carcinogenesis 30, 1857-1864
   Abstract »    Full Text »    PDF »
A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation.
L. Zhao, H. Dong, C. C. Zhang, L. Kinch, M. Osawa, M. Iacovino, N. V. Grishin, M. Kyba, and L. J.-s. Huang (2009)
J. Biol. Chem. 284, 26988-26998
   Abstract »    Full Text »    PDF »
A Rac GTPase-Activating Protein, MgcRacGAP, Is a Nuclear Localizing Signal-Containing Nuclear Chaperone in the Activation of STAT Transcription Factors.
T. Kawashima, Y. C. Bao, Y. Minoshima, Y. Nomura, T. Hatori, T. Hori, T. Fukagawa, T. Fukada, N. Takahashi, T. Nosaka, et al. (2009)
Mol. Cell. Biol. 29, 1796-1813
   Abstract »    Full Text »    PDF »
Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor {alpha} Homodimers.
T. Hornakova, J. Staerk, Y. Royer, E. Flex, M. Tartaglia, S. N. Constantinescu, L. Knoops, and J.-C. Renauld (2009)
J. Biol. Chem. 284, 6773-6781
   Abstract »    Full Text »    PDF »
An Unusual Insertion in Jak2 Is Crucial for Kinase Activity and Differentially Affects Cytokine Responses.
C. Haan, D. C. Kroy, S. Wuller, U. Sommer, T. Nocker, C. Rolvering, I. Behrmann, P. C. Heinrich, and S. Haan (2009)
J. Immunol. 182, 2969-2977
   Abstract »    Full Text »    PDF »
Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F.
X. Lu, L. J.-S. Huang, and H. F. Lodish (2008)
J. Biol. Chem. 283, 5258-5266
   Abstract »    Full Text »    PDF »
Dual Role of the Jak1 FERM and Kinase Domains in Cytokine Receptor Binding and in Stimulation-Dependent Jak Activation.
S. Haan, C. Margue, A. Engrand, C. Rolvering, H. Schmitz-Van de Leur, P. C. Heinrich, I. Behrmann, and C. Haan (2008)
J. Immunol. 180, 998-1007
   Abstract »    Full Text »    PDF »
Decidual Prolactin Silences the Expression of Genes Detrimental to Pregnancy.
L. Bao, C. Tessier, A. Prigent-Tessier, F. Li, O. L. Buzzio, E. A. Callegari, N. D. Horseman, and G. Gibori (2007)
Endocrinology 148, 2326-2334
   Abstract »    Full Text »    PDF »
Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors.
T. Kawashima, Y. C. Bao, Y. Nomura, Y. Moon, Y. Tonozuka, Y. Minoshima, T. Hatori, A. Tsuchiya, M. Kiyono, T. Nosaka, et al. (2006)
J. Cell Biol. 175, 937-946
   Abstract »    Full Text »    PDF »
Growth Hormone Regulation of Sex-Dependent Liver Gene Expression.
D. J. Waxman and C. O'Connor (2006)
Mol. Endocrinol. 20, 2613-2629
   Abstract »    Full Text »    PDF »
Binding of SH2-B Family Members within a Potential Negative Regulatory Region Maintains JAK2 in an Active State.
J. H. Kurzer, P. Saharinen, O. Silvennoinen, and C. Carter-Su (2006)
Mol. Cell. Biol. 26, 6381-6394
   Abstract »    Full Text »    PDF »
Phosphorylation of JAK2 at Serine 523: a Negative Regulator of JAK2 That Is Stimulated by Growth Hormone and Epidermal Growth Factor.
A. M. Mazurkiewicz-Munoz, L. S. Argetsinger, J.-L. K. Kouadio, A. Stensballe, O. N. Jensen, J. M. Cline, and C. Carter-Su (2006)
Mol. Cell. Biol. 26, 4052-4062
   Abstract »    Full Text »    PDF »
Subcellular localization and functions of the barley stem rust resistance receptor-like serine/threonine-specific protein kinase Rpg1.
J. Nirmala, R. Brueggeman, C. Maier, C. Clay, N. Rostoks, C. G. Kannangara, D. von Wettstein, B. J. Steffenson, and A. Kleinhofs (2006)
PNAS 103, 7518-7523
   Abstract »    Full Text »    PDF »
Active Conformation of the Erythropoietin Receptor: RANDOM AND CYSTEINE-SCANNING MUTAGENESIS OF THE EXTRACELLULAR JUXTAMEMBRANE AND TRANSMEMBRANE DOMAINS.
X. Lu, A. W. Gross, and H. F. Lodish (2006)
J. Biol. Chem. 281, 7002-7011
   Abstract »    Full Text »    PDF »
Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders.
R. L. Levine and G. Wernig (2006)
Hematology 2006, 233-239
   Abstract »    Full Text »    PDF »
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.
I. S. Lucet, E. Fantino, M. Styles, R. Bamert, O. Patel, S. E. Broughton, M. Walter, C. J. Burns, H. Treutlein, A. F. Wilks, et al. (2006)
Blood 107, 176-183
   Abstract »    Full Text »    PDF »
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
X. Lu, R. Levine, W. Tong, G. Wernig, Y. Pikman, S. Zarnegar, D. G. Gilliland, and H. Lodish (2005)
PNAS 102, 18962-18967
   Abstract »    Full Text »    PDF »
JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: CROSS-TALK WITH IGF1 RECEPTOR.
J. Staerk, A. Kallin, J.-B. Demoulin, W. Vainchenker, and S. N. Constantinescu (2005)
J. Biol. Chem. 280, 41893-41899
   Abstract »    Full Text »    PDF »
Janus Kinase 2 Enhances the Stability of the Mature Growth Hormone Receptor.
K. He, K. Loesch, J. W. Cowan, X. Li, L. Deng, X. Wang, J. Jiang, and S. J. Frank (2005)
Endocrinology 146, 4755-4765
   Abstract »    Full Text »    PDF »
Mechanisms of SOCS3 Phosphorylation upon Interleukin-6 Stimulation: CONTRIBUTIONS OF Src- AND RECEPTOR-TYROSINE KINASES.
U. Sommer, C. Schmid, R. M. Sobota, U. Lehmann, N. J. Stevenson, J. A. Johnston, F. Schaper, P. C. Heinrich, and S. Haan (2005)
J. Biol. Chem. 280, 31478-31488
   Abstract »    Full Text »    PDF »
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.
T. J. Boggon, Y. Li, P. W. Manley, and M. J. Eck (2005)
Blood 106, 996-1002
   Abstract »    Full Text »    PDF »
The Jak1 SH2 Domain Does Not Fulfill a Classical SH2 Function in Jak/STAT Signaling but Plays a Structural Role for Receptor Interaction and Up-regulation of Receptor Surface Expression.
S. Radtke, S. Haan, A. Jorissen, H. M. Hermanns, S. Diefenbach, T. Smyczek, H. Schmitz-VandeLeur, P. C. Heinrich, I. Behrmann, and C. Haan (2005)
J. Biol. Chem. 280, 25760-25768
   Abstract »    Full Text »    PDF »
A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases.
W. Vainchenker and S. N. Constantinescu (2005)
Hematology 2005, 195-200
   Abstract »    Full Text »    PDF »
Janus Kinase (Jak) Subcellular Localization Revisited: THE EXCLUSIVE MEMBRANE LOCALIZATION OF ENDOGENOUS JANUS KINASE 1 BY CYTOKINE RECEPTOR INTERACTION UNCOVERS THE Jak{middle dot}RECEPTOR COMPLEX TO BE EQUIVALENT TO A RECEPTOR TYROSINE KINASE.
I. Behrmann, T. Smyczek, P. C. Heinrich, H. Schmitz-Van de Leur, W. Komyod, B. Giese, G. Muller-Newen, S. Haan, and C. Haan (2004)
J. Biol. Chem. 279, 35486-35493
   Abstract »    Full Text »    PDF »
Autophosphorylation of JAK2 on Tyrosines 221 and 570 Regulates Its Activity.
L. S. Argetsinger, J.-L. K. Kouadio, H. Steen, A. Stensballe, O. N. Jensen, and C. Carter-Su (2004)
Mol. Cell. Biol. 24, 4955-4967
   Abstract »    Full Text »    PDF »
Jak3-Independent Trafficking of the Common {gamma} Chain Receptor Subunit: Chaperone Function of Jaks Revisited.
S. R. Hofmann, A. Q. Lam, S. Frank, Y.-J. Zhou, H. L. Ramos, Y. Kanno, D. Agnello, R. J. Youle, and J. J. O'Shea (2004)
Mol. Cell. Biol. 24, 5039-5049
   Abstract »    Full Text »    PDF »
Tyrosine 813 Is a Site of JAK2 Autophosphorylation Critical for Activation of JAK2 by SH2-B{beta}.
J. H. Kurzer, L. S. Argetsinger, Y.-J. Zhou, J.-L. K. Kouadio, J. J. O'Shea, and C. Carter-Su (2004)
Mol. Cell. Biol. 24, 4557-4570
   Abstract »    Full Text »    PDF »
Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation.
J. L. Roberts, A. Lengi, S. M. Brown, M. Chen, Y.-J. Zhou, J. J. O'Shea, and R. H. Buckley (2004)
Blood 103, 2009-2018
   Abstract »    Full Text »    PDF »
Janus Kinase 2 Determinants for Growth Hormone Receptor Association, Surface Assembly, and Signaling.
K. He, X. Wang, J. Jiang, R. Guan, K. E. Bernstein, P. P. Sayeski, and S. J. Frank (2003)
Mol. Endocrinol. 17, 2211-2227
   Abstract »    Full Text »    PDF »
A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity.
M. H. Shaw, V. Boyartchuk, S. Wong, M. Karaghiosoff, J. Ragimbeau, S. Pellegrini, M. Muller, W. F. Dietrich, and G. S. Yap (2003)
PNAS 100, 11594-11599
   Abstract »    Full Text »    PDF »
Autoinhibition of Jak2 Tyrosine Kinase Is Dependent on Specific Regions in Its Pseudokinase Domain.
P. Saharinen, M. Vihinen, and O. Silvennoinen (2003)
Mol. Biol. Cell 14, 1448-1459
   Abstract »    Full Text »    PDF »
Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies.
F. Ravandi, M. Talpaz, and Z. Estrov (2003)
Clin. Cancer Res. 9, 535-550
   Abstract »    Full Text »    PDF »
Dual Mechanism of Signal Transducer and Activator of Transcription 5 Activation by the Insulin Receptor.
M. N. Le, R. A. Kohanski, L.-H. Wang, and H. B. Sadowski (2002)
Mol. Endocrinol. 16, 2764-2779
   Abstract »    Full Text »    PDF »
The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction.
P. Saharinen and O. Silvennoinen (2002)
J. Biol. Chem. 277, 47954-47963
   Abstract »    Full Text »    PDF »
Identification of a JAK2-independent Pathway Regulating Growth Hormone (GH)-stimulated p44/42 Mitogen-activated Protein Kinase Activity. GH ACTIVATION OF Ral AND PHOSPHOLIPASE D IS Src-DEPENDENT.
T. Zhu, L. Ling, and P. E. Lobie (2002)
J. Biol. Chem. 277, 45592-45603
   Abstract »    Full Text »    PDF »
Regulation of Jak2 through the Ubiquitin-Proteasome Pathway Involves Phosphorylation of Jak2 on Y1007 and Interaction with SOCS-1.
D. Ungureanu, P. Saharinen, I. Junttila, D. J. Hilton, and O. Silvennoinen (2002)
Mol. Cell. Biol. 22, 3316-3326
   Abstract »    Full Text »    PDF »
SH2-B Family Members Differentially Regulate JAK Family Tyrosine Kinases.
K. B. O'Brien, J. J. O'Shea, and C. Carter-Su (2002)
J. Biol. Chem. 277, 8673-8681
   Abstract »    Full Text »    PDF »
Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation.
K. Lindauer, T. Loerting, K. R. Liedl, and R. T. Kroemer (2001)
Protein Eng. Des. Sel. 14, 27-37
   Abstract »    Full Text »    PDF »
Jaks and Stats as therapeutic targets.
J. J O'Shea, R. Visconti, T. P Cheng, and M. Gadina (2000)
Ann Rheum Dis 59, i115-118
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882